scispace - formally typeset
Journal ArticleDOI

Neuroleptic-Induced Supersensitivity Psychosis

Guy Chouinard, +2 more
- 01 Nov 1978 - 
- Vol. 135, Iss: 11, pp 1409-1410
Reads0
Chats0
TLDR
The anticholinergic effects of chlorpromazine, amitriptyline, scopolamine (Sominex) (0), and tropicamide were probably additive and although her disorientation cleared rapidly, Ms. A maintained that her hallucinations persisted during her 2-week hospitalization.
Abstract
drops from neurologic disease, pilocarpine, a parasympathomimetic agent, is safe and reliable. It causes ·constriction of the iris sphincter unless atropine or an·other postsynaptic blocker, such as tropicamide, the substance involved in this case, has been used. Physostigmine salicylate (Antilirium) was not used, · but it is effective in treating anticholinergic intoxica.' tion when administered intramuscularly (l mg repeated in 15-20 minutes if necessary). In Ms. A's case, the anticholinergic effects of chlorpromazine, amitriptyline, scopolamine (Sominex) (0), and tropicamide were probably additive. Although her disorientation cleared rapidly, Ms. A maintained that her hallucinations persisted during her 2-week hospitalization. However, it is difficult to know : whether this was actually the case. Given the previous diagnosis of Munch~lUsen syndrome and her unusual willingness to assume the psychiatric patient role as well as the medical-surgical patient role, it is not unlikely that she was attempting to prolong her hospitalization.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

TL;DR: Assessment of immediate and later follow-up treatment of psychotic patients indicates that moderate doses are adequate for most patients, and moderate doses of neuroleptics appear, on average, to be about as effective as, and probably safer than, the larger doses that have been popular in the United States in recent years.
Journal ArticleDOI

Update on the Clinical Efficacy and Side Effects of Clozapine

TL;DR: Although CLOZ has proven to be effective in some treatment-refractory schizophrenic patients and to produce relatively few extrapyramidal side effects compared to classical neuroleptics, several issues require further investigation including what defines neuroleptic intolerance, the optimal dose range, and the appropriate duration of a CLOz treatment trial.
Journal ArticleDOI

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

TL;DR: Clozapine therapy, performed in conjunction with close haematological monitoring, is indicated for the management of severe and chronic schizophrenia refractory to classic antipsychotic therapy, and in those unable to tolerate such therapy.
Journal ArticleDOI

Rapid Release of Antipsychotic Drugs From Dopamine D2 Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine

TL;DR: The rapid release of clozapine and quetiapine from D2 receptors by endogenous dopamine may contribute to low D2 receptor occupancy and to early clinical relapse upon withdrawal of these medications.
References
More filters
Journal ArticleDOI

Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity

TL;DR: The binding of [3H]haloperidol to rat striatal dopamine receptors increases after lesion (made by injection of 6-hydroxydopamine) of the nigrostriatal dopamine pathway in those rats which are behaviorally supersensitive, as reflected by apomorphine-induced contralateral rotations.
Journal ArticleDOI

Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol☆

TL;DR: Upon repeated administration of 7–21 daily doses of loxapine and haloperidol, the rats develop a very marked and fairly long-lasting tolerance toward the above actions of the drugs.
Journal ArticleDOI

Pseudoparkinsonism and Tardive Dyskinesia

George E. Crane
- 01 Nov 1972 - 
TL;DR: It is shown that tardive dyskinesia is more likely to develop in patients with pseudoparkinsonian symptoms than in patients not exhibiting such manifestations.
Journal ArticleDOI

Pharmacology of Neuroleptics upon Repeated Administration

TL;DR: Tolerance developed in all models involving stereotyped behaviour induced by central dopaminergic stimulation, whereas no tolerance developed to the cataleptogenic effect and the inhibition of conditioned avoidance reaction, dependent on pretreatment dose and length of pretreatment period.
Related Papers (5)